108 related articles for article (PubMed ID: 17216246)
1. Severe anemia caused by the angiotensin receptor blocker irbesartan after renal transplantation.
Simonetti GD; Bianchetti MG; Konrad M; von Vigier RO
Pediatr Nephrol; 2007 May; 22(5):756-7. PubMed ID: 17216246
[No Abstract] [Full Text] [Related]
2. Anaemia in dialysis patients as a side-effect of sartanes.
Schwarzbeck A; Wittenmeier KW; Hällfritzsch U
Lancet; 1998 Jul; 352(9124):286. PubMed ID: 9690412
[No Abstract] [Full Text] [Related]
3. Acute pancreatitis associated with irbesartan therapy.
Famularo G; Minisola G; Nicotra GC; De Simone C
Pancreas; 2005 Oct; 31(3):294-5. PubMed ID: 16163066
[No Abstract] [Full Text] [Related]
4. [Leukoneutropenia associated with irbesartan].
Gómez-Sayago L; Queizán Hernández JA; García-López L; Criado Illana MT
Farm Hosp; 2012; 36(4):302-3. PubMed ID: 22129651
[No Abstract] [Full Text] [Related]
5. Could irbesartan trigger autoimmune cholestatic hepatitis?
Annicchiarico BE; Siciliano M
Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):247-8. PubMed ID: 15674105
[No Abstract] [Full Text] [Related]
6. Teratogenicity with angiotensin II receptor antagonists in pregnancy.
Boix E; Zapater P; Picó A; Moreno O
J Endocrinol Invest; 2005 Dec; 28(11):1029-31. PubMed ID: 16483184
[TBL] [Abstract][Full Text] [Related]
7. Systemic illness with skin eruption, fever and positive lymphocyte transformation test in a patient on irbesartan.
Constable S; Farrell J; Naisbitt D; King C; Leonard N; Pirmohamed M
Br J Dermatol; 2006 Aug; 155(2):491-3. PubMed ID: 16882204
[No Abstract] [Full Text] [Related]
8. Irbesartan for heart failure with preserved ejection fraction.
Schillaci G; Pucci G; Pirro M
N Engl J Med; 2009 Mar; 360(12):1258; author reply 1258-9. PubMed ID: 19301450
[No Abstract] [Full Text] [Related]
9. Neurological picture. Orolingual angio-oedema after alteplase therapy in a stroke patient concurrently using angiotensin II receptor blocker.
Tan CH; Tang SC; Lin RJ; Jeng JS
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1079. PubMed ID: 20547619
[No Abstract] [Full Text] [Related]
10. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
[No Abstract] [Full Text] [Related]
11. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 1 receptor blockade does not enhance apoptotic cell death during ischemia and reperfusion in humans in vivo.
Meijer P; Wouters CW; Oyen WJ; Boerman OC; Scheffer GJ; Smits P; Rongen GA
J Cardiovasc Pharmacol; 2011 Jun; 57(6):702-6. PubMed ID: 21423028
[TBL] [Abstract][Full Text] [Related]
14. Hypotensive shock and angio-oedema from angiotensin II receptor blocker: a class effect in spite of tripled tryptase values.
Nielsen EW
J Intern Med; 2005 Oct; 258(4):385-7. PubMed ID: 16164579
[TBL] [Abstract][Full Text] [Related]
15. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Neutel JM; Germino FW; Smith D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
[TBL] [Abstract][Full Text] [Related]
16. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
18. [Cross reactivity between ACE inhibitors and angiotensin receptor blockers].
Rosenborg S
Lakartidningen; 2010 Feb 17-23; 107(7):444. PubMed ID: 20384078
[No Abstract] [Full Text] [Related]
19. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
Kawano Y; Sato Y; Yoshinaga K
Hypertens Res; 2008 Sep; 31(9):1753-63. PubMed ID: 18971554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
